Efficacy and safety of pregabalin in the management of low back pain: a comprehensive meta-analysis
Open Access
- 8 September 2025
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1659531
Abstract
Introduction: Low back pain (LBP) is one of the most prevalent chronic pain conditions that affects nearly 50% of the population. Its complex pathophysiology may involve both nociceptive and neuropathic mechanisms and is often resistant to standard treatment. Pregabalin has emerged as a potential alternative owing to its mechanism of action, the inhibition of excitatory neurotransmitter release. This meta-analysis aimed to evaluate the efficacy and safety of pregabalin in managing LBP.Methods: A systematic review of three major databases was conducted following the PRISMA guidelines. Studies were included if they were comparative studies of pregabalin with placebo or other pain medications, focusing on adult patients with LBP. Data were extracted on efficacy outcomes including pain reduction, anxiety, depression, quality of life, quality of sleep, disability, and adverse events. Statistical analysis was performed using Review Manager 5.4.1.Results: A total of 18 studies (n = 5,000) were included. Pregabalin demonstrated significant pain reduction at 4 weeks (Standardized Mean Difference (SMD) = −0.64, 95% Confidence Interval (CI) = −1.09 to −0.20), 6 weeks (SMD = −0.72, 95% CI = −1.15 to −0.29), and 8 weeks (SMD = −0.50, 95% CI = −0.71 to −0.29) compared to control group. Pregabalin also showed a significant greater improvement in anxiety (Mean Difference (MD) = −1.38, 95% CI = −1.74 to −1.02, p < 0.00001), depression (MD = −1.40, 95% CI = −1.71 to −1.08, p < 0.00001), quality of life (SMD = 0.22, 95% CI = 0.07 to 0.37, p = 0.003) and sleep quality (SMD = −0.61, 95% CI = −0.87 to −0.36, p < 0.00001). There were no significant differences regarding disability and adverse events.Conclusion: Pregabalin in the treatment of neuropathic LBP demonstrated significant improvements in pain relief, associated symptoms of anxiety and depression, and enhancements in quality of life and sleep quality. In addition, it exhibits a favorable safety profile. Nevertheless, these findings should be interpreted with caution due to the limited quality of the evidence and the inadequate reporting of pain etiology in several included studies.Keywords
This publication has 63 references indexed in Scilit:
- Effectiveness of pharmacological and non-pharmacological therapy on pain intensity and disability in older people with chronic nonspecific low back pain: a systematic review with meta-analysisEuropean Spine Journal, 2023
- Pharmacological treatments for low back pain in adults: an overview of Cochrane ReviewsCochrane Database of Systematic Reviews, 2023
- Healthcare expenditure and its predictors in a cohort of Australians living with sciaticaEuropean Spine Journal, 2020
- Opioids for chronic low back pain: An updated systematic review and meta‐analysis of efficacy, tolerability and safety in randomized placebo‐controlled studies of at least 4 weeks of double‐blind durationEuropean journal of pain, 2019
- Cochrane Handbook for Systematic Reviews of Interventions2019
- Effect of Gabapentin vs Pregabalin on Pain Intensity in Adults With Chronic SciaticaJAMA Neurology, 2019
- Neuropathic low back pain in clinical practiceEuropean journal of pain, 2016
- Non-steroidal anti-inflammatory drugs for chronic low back painCochrane Database of Systematic Reviews, 2016
- Pharmacological management of chronic low back pain in older patients: a randomized controlled trial of the effect of pregabalin and opioid administrationEuropean Spine Journal, 2015
- Patient-reported-outcomes in subjects with painful lumbar or cervical radiculopathy treated with pregabalin: evidence from medical practice in primary care settingsRheumatology International, 2009